Capricor Shares Set for Worst Month Since July Ahead of FDA Deramiocel Decision

what happened

According to Stocktwits, shares of Capricor Therapeutics (CAPR) dropped 11% on Wednesday, extending a multi-week slide. Investors are weighing the chances that the U.S. Food and Drug Administration approves Deramiocel, the company's lead therapy for Duchenne muscular dystrophy. The agency is due to decide by November 22. So far this month the stock has lost about 38%, putting it on track for its worst month since July, when an FDA advisory panel voted against the drug's effectiveness.

The FDA rejected Capricor's first application in July 2025. The company resubmitted with late-stage HOPE-3 data and later asked to narrow the label to upper-limb function. The agency treated that as a major amendment and moved the decision to November 22. Analysts are split: H.C. Wainwright sees only a small chance of approval, while Roth Capital considers a second FDA panel possible.

why it matters

Of the 10 analysts covering the stock, four rate it Buy or higher and six rate it Hold. The 12-month average price target is $27. For a single biotech name, a regulator's decision often becomes the main driver of the share price, so the selloff mainly reflects rejection risk rather than a broader sector trend.

market impact

Capricor shares: the FDA approval decision will set the direction; the wider biotech sector is only weakly affected

tags

instruments